Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients
Abstract. Objective:. Coronavirus disease 2019 (COVID-19) is a global public health crisis. There are no specific antiviral agents for the treatment of SARS-CoV-2. Information regarding the effect of Abidol on in-hospital mortality is scarce. The present study aimed to evaluate the treatment effect...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2021-03-01
|
| Series: | Cardiology Discovery |
| Online Access: | http://journals.lww.com/10.1097/CD9.0000000000000014 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849701467487731712 |
|---|---|
| author | Hesong Zeng Xingwei He Wanjun Liu Jing Kan Liqun He Jinhe Zhao Cynthia Chen Junjie Zhang Shaoliang Chen Tianyu Xu Xiaoxia Fu. |
| author_facet | Hesong Zeng Xingwei He Wanjun Liu Jing Kan Liqun He Jinhe Zhao Cynthia Chen Junjie Zhang Shaoliang Chen Tianyu Xu Xiaoxia Fu. |
| author_sort | Hesong Zeng |
| collection | DOAJ |
| description | Abstract. Objective:. Coronavirus disease 2019 (COVID-19) is a global public health crisis. There are no specific antiviral agents for the treatment of SARS-CoV-2. Information regarding the effect of Abidol on in-hospital mortality is scarce. The present study aimed to evaluate the treatment effect of Abidol for patients with COVID-19 before and after propensity score matching (PSM).
Methods:. This retrospective cohort study analyzed 1019 patients with confirmed COVID-19 in China from December 22, 2019 to March 13, 2020. Patients were divided to Abidol (200 mg, tid, 5–7 days, n = 788, 77.3%) and No-Abidol (n = 231, 22.7%) groups. The primary outcome was the mortality during hospitalization.
Results:. Among 1019 COVID-19 patients, the age was (60.4 ± 14.5) years. Abidol-treated patients, compared with No-Abidol-treated patients, had a shorter duration from onset of symptoms to admission, less frequent renal dysfunction, lower white blood cell counts (lymphocytes <0.8) and erythrocyte sending rate, lower interleukin-6, higher platelet counts and plasma IgG and oxygen saturation, and less frequent myocardial injury. The mortality during hospitalization before PSM was 17.9% in Abidol group and 34.6% in No-Abidol (hazard ratio (HR) = 2.610, 95% confident interval (CI): 1.980–3.440), all seen in severe and critical patients. After PSM, the in-hospital death was 13.6% in Abidol and 28.6% in No-Abidol group (HR = 2.728, 95% CI: 1.598–4.659).
Conclusions:. Abidol-treatment results in less in-hospital death for severe and critical patients with COVID-19. Further randomized study is warranted to confirm the findings from this study. |
| format | Article |
| id | doaj-art-c373a780aa3a4b9d8cc42c302dfe6788 |
| institution | DOAJ |
| issn | 2096-952X 2693-8499 |
| language | English |
| publishDate | 2021-03-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Cardiology Discovery |
| spelling | doaj-art-c373a780aa3a4b9d8cc42c302dfe67882025-08-20T03:17:55ZengWolters Kluwer Health/LWWCardiology Discovery2096-952X2693-84992021-03-0111374310.1097/CD9.0000000000000014202103000-00013Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 PatientsHesong ZengXingwei HeWanjun LiuJing KanLiqun HeJinhe ZhaoCynthia ChenJunjie ZhangShaoliang ChenTianyu XuXiaoxia Fu.Abstract. Objective:. Coronavirus disease 2019 (COVID-19) is a global public health crisis. There are no specific antiviral agents for the treatment of SARS-CoV-2. Information regarding the effect of Abidol on in-hospital mortality is scarce. The present study aimed to evaluate the treatment effect of Abidol for patients with COVID-19 before and after propensity score matching (PSM). Methods:. This retrospective cohort study analyzed 1019 patients with confirmed COVID-19 in China from December 22, 2019 to March 13, 2020. Patients were divided to Abidol (200 mg, tid, 5–7 days, n = 788, 77.3%) and No-Abidol (n = 231, 22.7%) groups. The primary outcome was the mortality during hospitalization. Results:. Among 1019 COVID-19 patients, the age was (60.4 ± 14.5) years. Abidol-treated patients, compared with No-Abidol-treated patients, had a shorter duration from onset of symptoms to admission, less frequent renal dysfunction, lower white blood cell counts (lymphocytes <0.8) and erythrocyte sending rate, lower interleukin-6, higher platelet counts and plasma IgG and oxygen saturation, and less frequent myocardial injury. The mortality during hospitalization before PSM was 17.9% in Abidol group and 34.6% in No-Abidol (hazard ratio (HR) = 2.610, 95% confident interval (CI): 1.980–3.440), all seen in severe and critical patients. After PSM, the in-hospital death was 13.6% in Abidol and 28.6% in No-Abidol group (HR = 2.728, 95% CI: 1.598–4.659). Conclusions:. Abidol-treatment results in less in-hospital death for severe and critical patients with COVID-19. Further randomized study is warranted to confirm the findings from this study.http://journals.lww.com/10.1097/CD9.0000000000000014 |
| spellingShingle | Hesong Zeng Xingwei He Wanjun Liu Jing Kan Liqun He Jinhe Zhao Cynthia Chen Junjie Zhang Shaoliang Chen Tianyu Xu Xiaoxia Fu. Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients Cardiology Discovery |
| title | Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients |
| title_full | Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients |
| title_fullStr | Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients |
| title_full_unstemmed | Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients |
| title_short | Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients |
| title_sort | antiviral abidol is associated with the reduction of in hospital mortality in covid 19 patients |
| url | http://journals.lww.com/10.1097/CD9.0000000000000014 |
| work_keys_str_mv | AT hesongzeng antiviralabidolisassociatedwiththereductionofinhospitalmortalityincovid19patients AT xingweihe antiviralabidolisassociatedwiththereductionofinhospitalmortalityincovid19patients AT wanjunliu antiviralabidolisassociatedwiththereductionofinhospitalmortalityincovid19patients AT jingkan antiviralabidolisassociatedwiththereductionofinhospitalmortalityincovid19patients AT liqunhe antiviralabidolisassociatedwiththereductionofinhospitalmortalityincovid19patients AT jinhezhao antiviralabidolisassociatedwiththereductionofinhospitalmortalityincovid19patients AT cynthiachen antiviralabidolisassociatedwiththereductionofinhospitalmortalityincovid19patients AT junjiezhang antiviralabidolisassociatedwiththereductionofinhospitalmortalityincovid19patients AT shaoliangchen antiviralabidolisassociatedwiththereductionofinhospitalmortalityincovid19patients AT tianyuxu antiviralabidolisassociatedwiththereductionofinhospitalmortalityincovid19patients AT xiaoxiafu antiviralabidolisassociatedwiththereductionofinhospitalmortalityincovid19patients |